

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Prevention, Screening, and Surveillance
Committee

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, October 8, 2026 2:00 p.m. - 4:00 p.m.
 Room: Regency A (Ballroom Level)

Agenda

1. Welcome and Opening Comments Banu Arun, MD &
 Jason Zell, DO

2. Presentation

"The CP-CTNet program and Portfolio of Clinical Trials" - Goli Samimi,
 PhD, MPH, Division of Cancer Prevention, National Cancer Institute

3. Triage and NCI Cancer Prevention Steering Committee Approved Studies

S2614, "A Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk Non-muscle Invasive Bladder Cancer (FIN-BC)." Drs. S. Psutka and P. Hensley.

4. Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

5. Concepts in Development

DCISionRT Biomarker for DCIS Concept, Dr. Eileen Connolly.

Prospective Trial of CRC Risk-Stratification and Screening in Young Adults Aged 35-44. Drs. Anoushka Dua, Li Hsu, Ulrike Peters, and Jason Zell.

QuitTech: A Technology-Enhanced Smoking Cessation Program for Cancer Patients and Survivors. Study Chair: Irene Tami-Maury, DMD, DrPH, MSc

6. Patient Advocate Update - Kristin McJunkins

7. Group Discussion

8. Other Group Prevention Studies with SWOG Accrual

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Banu Arun. Activated: 7/6/17. Closed: 12/20/24.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Prevention, Screening, & Surveillance Committee

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S9217 Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model. Vertosick EA, Goodman P, Tangen CM, Till C, Thompson IM, Lucia MS, Eastham J, Lilja H, Vickers AJ. European Urology Focus. 2026.
<https://pubmed.ncbi.nlm.nih.gov/41864782/>

S9217 No Evidence of Post-Finasteride Syndrome in 267,983 person-years follow-up in the Prostate Cancer Prevention Trial. Till C, Tangen C, Goodman P, Unger Thompson Jr. IM. Urology. 2026.
<https://pubmed.ncbi.nlm.nih.gov/42628582/> In press.

S1904 Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. Crew K, Anderson GL, Arnold K, Dzingle SA, Michel A, Delucie M, Law C, Pruthie S, Leon ACS, Shirley R, Gross-Perdekamp MT, Colanna S, Krisher Stacy, King T, Yee L, Ballinger T, Braun-Inglis C, Mangino D, Wisinski L, DeYoung CA, Ross M, Floyd J, Kaster A, Vanderwalde L, Saphner T, Zarwan CL, Lo S, Graham C, Conlin AK, Butler KY, Agnese DM, Jernigan C, Hershman DL, Neuhouser ML, Zell JA, Arun B, Kukafka R. Journal of the National Cancer Institute. 2026.
<https://pubmed.ncbi.nlm.nih.gov/42391096/>

Submitted Manuscripts

None this cycle.

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A212102	EA2185	EA8184	NRGCC005	NRGCC008
Audie L Murphy VA Hospital	69	-	4	4	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	3	-	-	6
CWRU Case Comprehensive Cancer Center LAPS	2	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	1	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	5	-	-	-	2
Henry Ford Hospital	7	-	-	-	-
Kansas City Veterans Affairs Medical Center	25	-	-	14	-
Loyola University Medical Center	8	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	40	-
Massachusetts Veterans Epidemiology Research and Information Center	32	8	-	97	-
Medical University of South Carolina NCORP Community Site	2	-	3	-	-
Northwell Health NCORP	-	-	-	-	1
Oregon Health and Science University	-	3	3	18	6
Our Lady of the Lake Hospital	4	-	-	-	-
The Don and Sybil Harrington Cancer Center	6	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	145	-	-	-	-
UC San Diego Moores Cancer Center	-	1	-	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-
University of California Davis Comprehensive Cancer Center	-	1	1	-	-
University of Colorado Cancer Center LAPS	5	-	-	21	-
University of Texas Health Science Center at San Antonio	20	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	14	-
Western States Cancer Research NCORP	1	-	-	-	-
Total	331	19	12	208	16

